Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML

Curtis A. Lachowiez, Vishvaas I Ravikumar, Jad Othman, Jenny O'Nions, Daniel T Peters, Christine McMahon, Ronan Swords, Rachel Cook, Jennifer N. Saultz, Jeffrey W. Tyner, Richard James Dillon, Joshua F. Zeidner, Daniel A. Pollyea

Blood blood.2024026925.

https://doi.org/10.1182/blood.2024026925

Published: 2024

Includes: Supplemental data

Journal Articles

Prognostic Impact of Secondary Versus De Novo Ontogeny in Acute Myeloid Leukemia (AML) Is Predominantly Accounted for By the European Leukemianet (ELN) 2022 Risk Classification

Michael J. Hochman, Megan Othus, Robert P. Hasserjian, Alexander J. Ambinder, Andrew M. Brunner, Mary-Elizabeth M. Percival, Christopher S. Hourigan, Ronan Swords, Amy E. DeZern, Elihu H. Estey, Judith E. Karp

Blood (2022) 140 (Supplement 1): 1430–1432.

https://doi.org/10.1182/blood-2022-164739

Published: 2022

Journal Articles

Ivosidenib (IVO) in Combination with Azacitidine (AZA) in Newly Diagnosed (ND) Older Patients with IDH1 R132-Mutated Acute Myeloid Leukemia (AML) Induces High Response Rates: A Phase 2 Sub-Study of the Beat AML Master Trial

Blood (2021) 138 (Supplement 1): 875.

https://doi.org/10.1182/blood-2021-149115

Published: 2021

Journal Articles

FLT3-Mutated Acute Myeloid Leukemia Using a Novel Regimen of Gemtuzumab Ozogamicin and Midostaurin in Combination with Standard Cytarabine and Daunorubicin Induction Therapy

Uma Borate, Andy Kaempf, Jessica Minnier, Shikha Misra, Shaun Goodyear, Gabrielle Meyers, Jennifer N. Saultz, Elie Traer, Ronan Swords, Rachel J. Cook, Sammantha Avaylon, Melissa Mackey, Brianna Norris, Roland B. Walter

Blood (2021) 138 (Supplement 1): 1269.

https://doi.org/10.1182/blood-2021-152791

Published: 2021

Journal Articles

Gilteritinib (GILT) Monotherapy with Addition of Decitabine (DEC) in Non-Responders in Older Newly Diagnosed (ND) FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Having High and Low Variant Allele Frequency (VAF): A Phase 2/1b Sub-Study of the Beat AML Master Trial

Blood (2021) 138 (Supplement 1): 1277.

https://doi.org/10.1182/blood-2021-148207

Published: 2021

Journal Articles

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome

Blood (2019) 134 (Supplement_1): 565.

https://doi.org/10.1182/blood-2019-124994

Published: 2019

Journal Articles

The Lysine-Specific Demethylase 1 (LSD1) Inhibitor Tranylcypromine (TCP) in Combination with ATRA Is Tolerable and Has Anti-Leukemic Activity in Adult Patients with Relapsed/Refractory AML and MDS

Justin M Watts, MD, Terrence J Bradley, MD, Amber Thomassen, MA, MSN, Yvonne Trang Dinh, BS, Dalissa Tejera, MSN, Kristen Englund, Sorab Boga, MPH, Randy Astaiza, BS, Charles J Chen, MPH, Malika Abdur-Rahman, BS, MSED, Marinescu Ion, CCRC, FMG, Aymee Perez, PhD, Masoumeh Tayari, PhD, Lluis Morey, PhD, Maria E. Figueroa, MD, Ramin Shiekhattar, PhD, Arthur Zelent, PhD, Ronan Swords, MD PhD

Blood (2018) 132 (Supplement 1): 2721.

https://doi.org/10.1182/blood-2018-99-115411

Published: 2018

Journal Articles

Alisertib (MLN8237), an Oral Selective Inhibitor of Aurora Kinase a, Has Clinical Activity and Restores GATA1 Expression in Patients with Myelofibrosis

Blood (2018) 132 (Supplement 1): 688.

https://doi.org/10.1182/blood-2018-99-110381

Published: 2018

Journal Articles

P53 Based Strategy to Reduce Hematological Toxicity of Chemotherapy: Emerging Support from a Phase II Trial

Chul S. Ha, MD, Joel Michalek, PhD, Richard Elledge, MD, Kevin R. Kelly, MD, PhD, Suthakar Ganapathy, PhD, Hang Su, PhD, Carol Jenkins, RN, BSN, Athanassios Argiris, MD, Ronan Swords, MD, PhD, Tony Y. Eng, MD, Anand Karnad, MD, Richard Crownover, MD, PhD, Gregory P Swanson, MD, Martin Goros, M.S., Brad H Pollock, MPH, PhD, Zhi-Min Yuan, MD, PhD

Blood (2014) 124 (21): 4809.

https://doi.org/10.1182/blood.V124.21.4809.4809

Published: 2014

Journal Articles

Analysis of the GeneXpert System on the International Multicentre ICORG 08–02 Phase II Study of Nilotinib 300mg BID as Frontline Treatment in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECPCML),

Michael E O'Dwyer, MD, FRCPI, FRCPath, Ronan Swords, MD, MRCPI, FRCPath, Francis Giles, MD FRCPI FRCPath, Mary Frances McMullin, MD, Philipp D. le Coutre, MD, Arnon Nagler, Stephen Langabeer, Marzena Wieczorkowska, Cliona McDowell, Karine Egan, Brian Moulton, Eibhlin Conneally, MB, MRCPI, FRCPath, PhD

Blood (2011) 118 (21): 3774.

https://doi.org/10.1182/blood.V118.21.3774.3774

Published: 2011

Journal Articles

Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias

Hima Bansal, Sanjay Bansal, Manjeet Rao, Kevin P. Foley, Jim Sang, David A. Proia, Ronald K. Blackman, Weiwen Ying, James Barsoum, Maria R. Baer, Kevin Kelly, Ronan Swords, Gail E. Tomlinson, Minoo Battiwalla, Francis J. Giles, Kelvin P. Lee, Swaminathan Padmanabhan

Blood (2010) 116 (22): 4591–4599.

https://doi.org/10.1182/blood-2009-10-247239

Published: 2010

Includes: Supplemental data

Journal Articles

A New Rotary Powered Device for Bone Marrow Aspiration and Biopsy Yields Superior Specimens with Less Pain: Results of a Randomized Clinical Study

Ronan Swords, MD, MRCPI, FRCPath, Javier Anguita, MD, Russell A. Higgins, MD, Andrea Yunes, MD, Michael Naski, MD, PhD, Swaminathan Padmanabhan, MD, Kevin R Kelly, MD, Devalingam Mahalingam, MD, PhD, Thomas Philbeck, PhD, Larry Miller, MD, Francis J. Giles, MB, MD, FRCPI, FRCPath, Marsha Kinney, MD, Andrew Brenner, MD

Blood (2010) 116 (21): 1529.

https://doi.org/10.1182/blood.V116.21.1529.1529

Published: 2010

Journal Articles

A Pilot Study of the Combination of Nilotinib and Hyper-CVAD for Philadelphia Chromosome Positive Acute Lymphocytic Leukemia and Lymphoid Blast Crisis Chronic Myelogenous Leukemia

Edgar Castillo, Raed Al-Rajabi, Devesh M. Pandya, MD, Prakash Varadarajan, MD, Kevin R Kelly, MD, Ronan Swords, MD, MRCPI, FRCPath, Anita Tharian, DO, Mary K. Kraus, Swaminathan Padmanabhan, MBBS, MD

Blood (2010) 116 (21): 2144.

https://doi.org/10.1182/blood.V116.21.2144.2144

Published: 2010

Journal Articles

A Phase I Study of the Potent Hsp90 Inhibitor STA-9090 Administered Twice Weekly In Subjects with Hematologic Malignancies

Swaminathan Padmanabhan, MBBS, MD, Kevin R Kelly, MD, Mark Heaney, MD, PhD, Stephanie Hodges, Suzanne Chanel, RN, Mark Frattini, MD, Ronan Swords, MD, MRCPI, FRCPath, Robert Bradley, Florentina Teofilovici, MD, MS, Daniel J DeAngelo, MD, PhD

Blood (2010) 116 (21): 2898.

https://doi.org/10.1182/blood.V116.21.2898.2898

Published: 2010

Journal Articles

The Aurora Kinase Inhibitor MLN8237 Has Potent Anticancer Activity in CML and Ph+ ALL Models and Significantly Increases the Efficacy of Nilotinib

Steffan T. Nawrocki, Ph.D., Ernest Medina, B.S., Sabrina Smith, B.S., Ronan Swords, M.D., Kevin Kelly, M.D., Swaminathan Padmanabhan, M.D., Jeffrey Ecsedy, Ph.D., Francis J Giles, M.D., Jennifer Carew, Ph.D.

Blood (2008) 112 (11): 3198.

https://doi.org/10.1182/blood.V112.11.3198.3198

Published: 2008

NARROW

Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML

Prognostic Impact of Secondary Versus De Novo Ontogeny in Acute Myeloid Leukemia (AML) Is Predominantly Accounted for By the European Leukemianet (ELN) 2022 Risk Classification

Ivosidenib (IVO) in Combination with Azacitidine (AZA) in Newly Diagnosed (ND) Older Patients with IDH1 R132-Mutated Acute Myeloid Leukemia (AML) Induces High Response Rates: A Phase 2 Sub-Study of the Beat AML Master Trial

FLT3-Mutated Acute Myeloid Leukemia Using a Novel Regimen of Gemtuzumab Ozogamicin and Midostaurin in Combination with Standard Cytarabine and Daunorubicin Induction Therapy

Gilteritinib (GILT) Monotherapy with Addition of Decitabine (DEC) in Non-Responders in Older Newly Diagnosed (ND) FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Having High and Low Variant Allele Frequency (VAF): A Phase 2/1b Sub-Study of the Beat AML Master Trial

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome

The Lysine-Specific Demethylase 1 (LSD1) Inhibitor Tranylcypromine (TCP) in Combination with ATRA Is Tolerable and Has Anti-Leukemic Activity in Adult Patients with Relapsed/Refractory AML and MDS

Alisertib (MLN8237), an Oral Selective Inhibitor of Aurora Kinase a, Has Clinical Activity and Restores GATA1 Expression in Patients with Myelofibrosis

P53 Based Strategy to Reduce Hematological Toxicity of Chemotherapy: Emerging Support from a Phase II Trial

Analysis of the GeneXpert System on the International Multicentre ICORG 08–02 Phase II Study of Nilotinib 300mg BID as Frontline Treatment in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECPCML),

Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias

A New Rotary Powered Device for Bone Marrow Aspiration and Biopsy Yields Superior Specimens with Less Pain: Results of a Randomized Clinical Study

A Pilot Study of the Combination of Nilotinib and Hyper-CVAD for Philadelphia Chromosome Positive Acute Lymphocytic Leukemia and Lymphoid Blast Crisis Chronic Myelogenous Leukemia

A Phase I Study of the Potent Hsp90 Inhibitor STA-9090 Administered Twice Weekly In Subjects with Hematologic Malignancies

The Aurora Kinase Inhibitor MLN8237 Has Potent Anticancer Activity in CML and Ph+ ALL Models and Significantly Increases the Efficacy of Nilotinib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only